IndraLab
Statements
sparser
"In the context of melanoma, oncogenic BRAF V600E constitutively phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, hyperactivating the canonical Mitogen Activated Protein Kinase Pathway (MAPK) to promote uncontrolled melanocytes growth and caner initiation and progression xref ."
reach
"Immunoprecipitated BRAF (V600E) phosphorylated MEK1 protein in vitro (XREF_FIG, lane 5), however, treatment with 17-DMAG clearly inactivated the kinase activity of BRAF (V600E) (XREF_FIG, lane 6), even though equivalent levels of BRAF (V600E) protein were utilized from treated and non treated cell lysates (XREF_FIG, lanes 3 and 4)."
reach
"Although both BRAF V600E or BRAF WT phosphorylates MBP but such phosphorylation was not affected in the presence of increasing concentrations of acetoacetate or 3-HB (XREF_FIG and XREF_SUPPLEMENTARY), suggesting that acetoacetate may specifically affect BRAF V600E dependent phosphorylation of MEK1."
reach
"BRAF phosphorylates regulatory serine residues on MEK1 and MEK2 and mutation of BRAF results in activation of the RAS/RAF/MEK/ERK pathway, leading to cellular proliferation and a series of anti-apoptotic and potentially immunoregulatory events that culminate in the progression of this tumor."
sparser
"BRAF phosphorylates regulatory serine residues on MEK1 and MEK2 and mutation of BRAF results in activation of the RAS/RAF/MEK/ERK pathway, leading to cellular proliferation and a series of anti-apoptotic and potentially immunoregulatory events that culminate in the progression of this tumor."